Table 3 Characteristics of study participants

  Gender

5 females, 2 males

  Age at interview

6–16 years (mean 12 years, 4 ≤ 12 years and 3 > 12 years)

  Disease duration

4–6 months (mean 5.6 months)^a

  Diagnosis

Oligo JIA (2), Poly JIA (2), Enthesitis-related JIA (1), Juvenile dermatomyositis (1), Behcets disease (1)

  Medications received

Methotrexate (oral or s.c.) in combination with etanercept (Enbrel/Benepali) s.c (3) or tocilizumab (RoActemra) s.c. (1), etanercept (Enbrel) s.c. (1), methotrexate (Metex) s.c. (1) and adalimumab (Humira) s.c (1)

  Gender

7 females, 1 male

  Gender

6 females, 3 males

  Age at time of focus group

11–13 years (mean 12 years) in the first group and 14–17 years (mean 15.8 years) in the second group.

  Disease duration

6 months – 15 years (mean 8.1 years)

  Diagnosis

Unspecified JIA (5), Oligo JIA (1), Poly JIA (2), Systemic JIA (1) (self-reported)

  Medications received

Methotrexate (oral or s.c.) in combination with etanercept (Enbrel/Benepali) s.c (3) or tocilizumab (RoActemra) s.c. (1), methotrexate (Metex) s.c. (3), tocilizumab (RoActemra) i.v. (1) (earlier s.c. medication) and methotrexate oral (1) (earlier s.c. medication)^b

  Gender

5 females, 3 males

  Disease duration (child)

1–15 years (mean 7.2 years)

  Diagnosis (child)

Unspecified JIA (5), Poly JIA (2), Systemic JIA (1) (self-reported)

  Medications received (child)

Methotrexate (oral in combination with etanercept (Enbrel) s.c (2) or adalimumab. (Humira) s.c (1), methotrexate (Metex) s.c. (2), and methotrexate oral (2)